Sleep Stack: DSIP + Selank + Circadian Peptides Protocol (2026)

Sleep Stack: DSIP + Selank + Circadian Peptides Protocol (2026)
Educational use only. This article is informational and does not constitute medical advice. Peptide dosing decisions should be made in consultation with a licensed physician familiar with your medical history. Always verify any dose with your prescribing physician before drawing or administering. DSIP, Selank, Epitalon, and Pinealon are research peptides in the United States, not FDA-approved for any indication. Selank and Semax are registered as pharmaceuticals in Russia but not in the US. Regulatory status shifted following the February 27, 2026 HHS reclassification and continues to evolve pending the July 23-24, 2026 Pharmacy Compounding Advisory Committee review. Verify current status with a licensed compounding pharmacy or physician before ordering.

The Sleep Stack pairs three research peptides that act on non-overlapping axes of sleep biology: DSIP (Delta Sleep-Inducing Peptide, the nonapeptide that enhances slow-wave EEG activity during NREM sleep), Selank (a synthetic tuftsin analog with GABAergic anxiolytic activity, targeting pre-sleep rumination and anxiety), and a Khavinson circadian bioregulator — either Epitalon (the pineal tetrapeptide that restores nocturnal melatonin secretion) or Pinealon (the tripeptide alternative with a CNS-neuroprotective bias). The rationale is mechanistic complementarity: DSIP deepens the sleep you already have, Selank helps you fall into it, and the Khavinson course upstream-corrects the circadian signal that gates the whole system. This guide covers the nightly protocol for DSIP and Selank plus the twice-yearly Epitalon or Pinealon course, with reconstitution math, honest evidence grading, side-effect management, and a 2026 cost breakdown. See our individual guides for full pharmacology on each component: DSIP Guide, Selank Guide, Epitalon Guide, and Pinealon Guide. For the ranked comparison of every sleep-relevant peptide, see our Best Peptides for Sleep and Restoration pillar.

Table of Contents

What is the Sleep Stack?

The Sleep Stack is a three-peptide protocol combining an EEG-active sleep deepener (DSIP), a GABAergic wind-down peptide (Selank), and an upstream pineal-axis reset (Epitalon or Pinealon). It is not a formal medical protocol. There is no combination clinical trial, no manufacturer-published stacking guidance, and no FDA-approved indication for any of the three peptides. What exists is a mechanistic argument for combining them and a substantial base of community reporting of subjective benefit. This guide treats the stack the way it should be treated in 2026: as an informed-personal-use protocol backed by uneven evidence, presented with honest grading.

DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight 849 Da. It was isolated in the mid-1970s by the Schoenenberger and Monnier group in Basel from cerebral dialysates of rabbits whose sleep had been electrically induced, and characterized in 1977 (Schoenenberger, PMID 265572; PMID 568769). Its name derives from a demonstrated ability to enhance delta-EEG activity — the slow-wave phase of NREM sleep — by approximately 35% when infused intraventricularly in rabbits under double-blind conditions. In the four decades since discovery, its receptor has not been identified, its precursor protein has not been characterized, and no independent Western replication of the sleep effect at scale has been published. What has been published is small, older, and mostly favorable to a modest sleep-enhancing effect (Schneider-Helmert 1981, PMID 7028502; Kastin review, PMID 6689058).

Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, molecular weight 751.9 Da, developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences by extending the endogenous immune peptide tuftsin with a C-terminal Pro-Gly-Pro to improve metabolic stability. It is registered in Russia as an anxiolytic nasal-drop pharmaceutical (0.15% solution) for generalized anxiety disorder and neurasthenia, but is a research peptide in the United States. Its mechanism is multi-modal: positive allosteric modulation at GABA-A receptors (Volkova et al., PMID 28293190), inhibition of enkephalin-degrading enzymes (Zozulya et al., PMID 11550013), and serotonergic enhancement. In the Sleep Stack, Selank’s role is anxiolysis in the wind-down window, not direct sleep induction. Its evidence grade for anxiolysis is C (real human RCT-adjacent data, but not Western-replicated); its evidence grade for a direct sleep effect is D (inferred from anxiolysis reducing sleep-onset rumination, not from any sleep-EEG data).

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, molecular weight approximately 390 Da, developed by Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology in the 1990s. It is one of the Khavinson “peptide bioregulators” — short peptides proposed to cross cell membranes, interact directly with promoter regions of specific genes, and modulate transcription. For sleep, the relevant claim is restoration of nocturnal melatonin secretion in senescent systems (Khavinson 2001, PMID 11524632; Anisimov / Korenevsky 2004, PMID 15452611; Goncharova PMID 17969590; 2025 Biomedicines overview, PMID 40141333). The critical caveat: essentially every published human study of Epitalon originates from Khavinson’s group. Independent Western replication in adequately powered, placebo-controlled trials does not exist. Evidence grade is C for the melatonin-restoration claim (real human data but single-group), D for broader anti-aging claims translated to sleep.

Pinealon is a synthetic tripeptide, Glu-Asp-Arg (EDR), also a Khavinson-group short-peptide bioregulator, engineered specifically for CNS neuroprotective targets. Its proposed mechanism is the same DNA-promoter-interaction model as Epitalon, applied to genes governing neuronal survival, oxidative-stress response, and cognitive function. Formal peer-reviewed human trials of Pinealon are essentially absent from the Western record; evidence grade for sleep is D. In the Sleep Stack it functions as an alternative to Epitalon, not an add-on. Pick one, run the course, then decide whether to swap for the other on the next cycle.

How the Stack Works

The three peptides address disjoint physiology, which is why the community treats them as complementary rather than redundant. There is no receptor competition and no known pharmacokinetic interaction. The mechanistic argument for combining them runs as follows.

DSIP delta-wave enhancement. The Schoenenberger group’s original characterization of DSIP centered on a demonstrated increase in delta-EEG amplitude and duration during NREM sleep in rabbits, with a downstream extension to humans in the 1981 Schneider-Helmert trial (PMID 7028502). Slow-wave sleep is the phase most strongly associated with subjective restoration, glymphatic clearance of neural waste products, memory consolidation, and growth-hormone pulse coupling. DSIP’s proposed role in the stack is quality — deeper, more consolidated NREM — not quantity. The peptide’s mechanism 40 years on remains poorly characterized: Kovalzon’s 2006 review in Journal of Neurochemistry concluded that the mechanistic story is “extremely poorly documented and still weak” and that a DSIP-like endogenous peptide likely exists but has never been unambiguously isolated from human tissue. Downstream effects that have been measured but not receptor-linked include modulation of stress-axis hormones (blunted ACTH and cortisol), possible opioidergic activity, mild antioxidant activity, and mild pain-modulatory activity (PMIDs 6548966, 6548967, 6689058).

Selank GABAergic anxiolysis. Selank is a positive allosteric modulator at GABA-A receptors, producing a benzodiazepine-comparable anxiolytic effect without benzodiazepine-style tolerance or dependence signaling (Volkova et al., PMID 28293190). Independently, Selank inhibits enkephalin-degrading enzymes with an IC50 around 15 μM (Zozulya et al., PMID 11550013), raising endogenous enkephalin tone as a mechanistically-distinct anxiolytic pathway. Serotonergic enhancement in the brainstem (Semenova group) adds a mood-anxiety dimension. In the Sleep Stack, Selank is the pre-sleep wind-down. Its role is not to induce sleep but to lower the cognitive and physiological arousal that keeps sleep from starting. Users whose sleep onset is delayed by rumination or physical tension typically feel Selank’s effect within 20-40 minutes of intranasal administration.

Epitalon or Pinealon circadian reset. The Khavinson bioregulators are not nightly-use compounds. They are dosed as short intensive courses — typically 10-20 consecutive days of subcutaneous injection — twice a year. The proposed mechanism is upstream: Epitalon has been shown in the Khavinson corpus to restore nocturnal melatonin secretion in senescent macaques (PMID 11524632) and elderly humans (PMID 15452611, 17969590). The 2025 Biomedicines overview (PMID 40141333) summarizes 25 years of Epitalon research including geroprotective and neuroendocrine endpoints. What this means for the Sleep Stack is that Epitalon (or Pinealon) periodically re-anchors the circadian melatonin signal that DSIP and Selank ride on top of. The catch: the Khavinson corpus has essentially no independent Western replication. The Alzheimer’s Discovery Foundation has flagged this explicitly in its Cognitive Vitality Researcher report on Epithalamin/Epithalon. Take the mechanism as plausible; take the Khavinson-group efficacy claims as promising but not confirmed.

Non-overlapping mechanisms is the whole argument. Because each peptide acts on a different system — undefined DSIP receptor pathway for slow-wave deepening; GABA-A + serotonin + enkephalinase for Selank; pineal gene-expression modulation for Epitalon or Pinealon — the theoretical case for stacking is additive end-benefit without receptor competition. There are no published combination pharmacokinetic or safety studies. Users and clinicians reasoning about this stack are extrapolating from single-peptide data.

2026 Regulatory Status

DSIP. Not FDA-approved for any indication. Following the February 27, 2026 HHS peptide framework reclassification, DSIP falls in Category 1 (compoundable by 503A pharmacies with appropriate documentation). It is not on the current published list of seven peptides under the July 23-24, 2026 Pharmacy Compounding Advisory Committee review, though verify current post-review status before ordering. Research-peptide vendors sell DSIP as “research use only” outside the compounding-pharmacy regulatory framework; these products are not intended for human use and quality varies dramatically.

Selank. Registered as a pharmaceutical in Russia (0.15% intranasal drops), approved for generalized anxiety disorder and neurasthenia. Research peptide in the United States, on the July 2026 PCAC review agenda. Post-February-27-2026 compounding status pending PCAC outcomes — verify with a specific 503A pharmacy before ordering. Pharmaceutical-grade Russian Selank is legally imported for personal use in some jurisdictions; US customs enforcement has been inconsistent.

Epitalon. Not FDA-approved. Research peptide in the United States, on the July 2026 PCAC review agenda alongside BPC-157, TB-500, Semax, DSIP, and others. Not registered as a pharmaceutical in Russia despite decades of Khavinson-group clinical work. Compounded via 503A pharmacies with a prescription; some pharmacies decline given the thin Western evidence base.

Pinealon. Not FDA-approved. Research peptide in the United States. Not on the current published July 2026 PCAC review list — verify before publishing changes. Not registered as a pharmaceutical in Russia. Availability is essentially limited to research-peptide vendors and a small subset of compounding pharmacies.

Combining them. No FDA guidance addresses the combination. No published drug-drug interaction studies exist. Clinicians who prescribe compounded versions of any of these peptides alongside prescribed medications typically document the rationale in the medical record and monitor for unexpected effects. All three are contraindicated in pregnancy and lactation per the standard research-peptide caveat.

Standard Protocol (Community Modal)

This is the most-reported community protocol for the DSIP + Selank + Khavinson-bioregulator stack as of mid-2026. It targets steady-state sleep improvement with minimal disruption to daytime function. DSIP and Selank are nightly; the Khavinson component runs as two short courses per year. Total nightly protocol runs continuously with periodic cycling.

ComponentRouteTimingDoseFrequency
SelankIntranasal (0.15% or 0.20% solution)60-90 min before intended sleep300-600 mcg (split across nostrils)Nightly, 14 days on / 7 off
DSIPSubcutaneous, abdomen or thigh30-60 min before intended sleep200 mcg (range 100-300 mcg)Nightly, 3-4 wks on / 1-2 wks off
Epitalon (course only)SubcutaneousEvening (mechanism-consistent)5-10 mg per day10-day course, 2x per year
Pinealon (alternative course)SubcutaneousEvening1-2 mg per day10-20 day course, 2-3x per year

Nightly sequence. A realistic community sequence for a target 10:30 PM sleep time:

  • 9:00 PM (90 min pre-bed): Selank intranasal, 300 mcg per nostril = 600 mcg total dose. Sit upright for 5 minutes after administration to allow absorption.
  • 9:45 PM (45 min pre-bed): DSIP subcutaneous injection, 200 mcg, abdominal fat pad preferred. Rotate sites nightly.
  • 10:00-10:30 PM: Wind-down routine — dim lights, no screens, no additional stimulant intake. The 2-hour post-injection active window from the 1981 Schneider-Helmert DSIP trial (PMID 7028502) covers the intended sleep window.

Cycling logic. Selank’s Russian package insert pattern is 14 days on / 7-day washout, then repeat. Community protocols often continue nightly without a formal washout; the 14/7 pattern is a conservative default that preserves the freshness of the anxiolytic effect. DSIP is tolerated nightly per community reports without documented tolerance, but a 3-4 week on / 1-2 week off pattern is common for the same reason — subjective preservation of the sleep-deepening effect, not because published tolerance data require it. Epitalon and Pinealon are cyclical by mechanism: the Khavinson-published protocol is short intensive courses (10-20 days) two to three times per year, not chronic daily dosing.

Khavinson course timing within the year. Community pattern is roughly one Epitalon or Pinealon course in the fall (September-October) as circadian misalignment risk rises with shortened daylight, and one in the spring (March-April) at the daylight-savings transition. Users with jet-lag exposure sometimes run an extra 10-day course after major time-zone changes. There is no clinical trial data supporting a specific seasonal pattern; the seasonal framing is community heuristic.

Adjunct interventions. The stack works best inside a functional sleep-hygiene envelope. That means: consistent sleep and wake times within a 30-minute window, cool bedroom (65-68 °F), no alcohol within 3 hours of intended sleep (alcohol suppresses SWS and blunts DSIP’s slow-wave enhancement — this is the biggest single stack-undermining factor), reduced caffeine after noon, and dimmed evening light exposure. Without these baseline conditions, the stack still produces some effect, but the peptides are working uphill against modifiable behavioral disruptions.

For deep guidance on peptide timing generally, see our Peptide Timing Guide. For lab tracking of subjective and objective sleep response, see our Peptide Lab Testing Guide.

Aggressive / Deep Reset Variant

This variant is used by users with chronic severe insomnia, prolonged shift-work disruption, or extended jet-lag misalignment who want a maximal reset. It compresses the timeline for perceptible effect at the cost of higher total peptide exposure and more monitoring. Not recommended without medical oversight if the user is on prescribed sleep or anxiety medications. Duration: 8-week initial reset, then transition to the Standard protocol.

ComponentWeeks 1-2Weeks 3-4Weeks 5-8Notes
Selank intranasal600-900 mcg pre-bed + 300 mcg mid-afternoon600 mcg pre-bed only300-600 mcg pre-bedFront-load anxiolytic effect
DSIP SC300 mcg pre-bed300 mcg pre-bed200 mcg pre-bedHigher initial dose, taper to standard
Epitalon SC (course)10 mg daily, days 1-10——Front-loaded course in weeks 1-2
Optional: melatonin PO4 mg at 3 hours pre-bed4 mg at 3 hours pre-bedTaper or discontinuePer Cruz-Sanabria 2024 (PMID 38888087)

Why this is aggressive. Higher DSIP dose (300 mcg nightly) is at the upper end of the community range. Split Selank dosing (both a pre-bed and mid-afternoon dose in the first two weeks) doubles daily peptide exposure. Front-loading the Epitalon course in the first two weeks means the circadian reset is happening simultaneously with the acute nightly interventions rather than sequentially. Some users find this too much sensory shift at once and drop back to the Standard protocol. The variant is designed to be transitional — after 8 weeks the user should already be on the Standard protocol.

Adding melatonin is optional but supported by strong evidence. Cruz-Sanabria 2024 (PMID 38888087, Journal of Pineal Research, systematic review and dose-response meta-analysis of 26 RCTs) established that 4 mg oral melatonin taken 3 hours before intended sleep optimizes both sleep-onset latency reduction and total sleep time increase. The common US OTC pattern (5-10 mg immediate release just before bed) is supra-physiologic and mis-timed. If adding melatonin to the aggressive variant, use 4 mg at the 3-hour mark, not high-dose at bedtime.

Sex-caveat on GH-secretagogue add-ons. Some users layer a low-dose CJC-1295 + Ipamorelin GHRH/ghrelin-analog combination onto this variant for growth-hormone-pulse-mediated slow-wave enhancement (Steiger corpus, PMIDs 1361964, 15538933, 16912060, 12388174). This is not recommended for women. A 2007 Steiger study (PMID 17850984) showed peripheral GHRH impairs sleep in healthy young women and elevates ACTH and cortisol — the opposite of the intended effect. The GHRH-analog slow-wave enhancement documented in the Steiger corpus is essentially male-specific. See our CJC-1295 Guide and Ipamorelin Guide for full detail.

Conservative / Physician-Guided Variant

This variant is designed for users who are working closely with a physician, are on prescribed medications with known GABAergic or serotonergic activity, or are cautious about layered peptide exposure. It slows the introduction of each component so a physician can attribute any subjective change to a specific peptide, and reserves the Khavinson course for users whose sleep decline correlates with age-related circadian markers (measured 6-sulfatoxymelatonin or DLMO if available). Duration: 12-16 weeks staged introduction.

ComponentWeeks 1-4Weeks 5-8Weeks 9-12Weeks 13+
Selank300 mcg pre-bed onlyContinue if beneficialContinue or 14/7 cycling14 on / 7 off
DSIP—100 mcg pre-bed (start dose)150-200 mcg pre-bed200 mcg pre-bed, 3 wks on / 1 wk off
Epitalon course———Consider after 12 weeks if physician-approved and clinically indicated

Rationale. Introducing Selank alone in weeks 1-4 lets the user (and the prescribing physician) attribute any change in sleep-onset latency, anxiety, or subjective sleep quality to Selank specifically. Adding DSIP at week 5 at the low end of the community range (100 mcg) provides a similar attribution window. The Khavinson course is deferred to week 12+ and only run if there is a clinically relevant reason — measured low nocturnal melatonin, documented circadian misalignment, or a physician-driven trial with informed consent.

Best-for-whom. Users on prescribed SSRIs or SNRIs who need to move carefully around the theoretical Selank-plus-SSRI serotonergic additivity. Users on prescribed benzodiazepines whose prescriber wants to monitor for additive anxiolysis (Kozlovskaya-group animal data suggests Selank enhances diazepam anxiolysis). Users over 65 who metabolize peptides slightly differently. Users with a physician who prefers cautious peptide introduction generally.

Reconstitution Math

All three (or four, if using both Epitalon and Pinealon in different courses) peptides arrive lyophilized. Reconstitute with bacteriostatic water for injection (BAC water, 0.9% benzyl alcohol preservative). U-100 insulin syringes are the standard — 100 units = 1 mL. Selank pre-mixed nasal spray formulations skip the reconstitution step; the concentration is typically labeled on the bottle.

DSIP reconstitution:

Vial sizeBAC waterConcentrationDraw for 100 mcgDraw for 200 mcgDraw for 300 mcg
5 mg powder2 mL2.5 mg/mL (2500 mcg/mL)0.04 mL = 4 units U-1000.08 mL = 8 units0.12 mL = 12 units
5 mg powder2.5 mL2 mg/mL (2000 mcg/mL)0.05 mL = 5 units0.10 mL = 10 units0.15 mL = 15 units
10 mg powder2 mL5 mg/mL (5000 mcg/mL)0.02 mL = 2 units0.04 mL = 4 units0.06 mL = 6 units
10 mg powder4 mL2.5 mg/mL (2500 mcg/mL)0.04 mL = 4 units0.08 mL = 8 units0.12 mL = 12 units

Selank reconstitution (for users doing DIY intranasal from lyophilized vials):

Vial sizeBAC water / salineConcentrationPer drop (~50 μL)Per 0.10 mL spray
5 mg powder2 mL preservative-free saline2.5 mg/mL~125 mcg per drop250 mcg per 0.10 mL
5 mg powder3 mL saline1.67 mg/mL~83 mcg per drop167 mcg per 0.10 mL
30 mg pre-mixed nasal sprayN/A (pre-mixed 0.20%)2 mg/mL~100 mcg per drop200 mcg per spray
Russian pharma nasal dropsN/A (0.15%)1.5 mg/mL~75 mcg per drop150 mcg per 0.10 mL

Note on Selank intranasal reconstitution: Preservative-free saline is often preferred over BAC water for intranasal use because the benzyl alcohol preservative in BAC water can be mildly irritating to nasal mucosa. Some users use both — BAC water for injectable peptides and preservative-free saline for intranasal. Store reconstituted Selank refrigerated; discard after 30 days.

Epitalon reconstitution:

Vial sizeBAC waterConcentrationDraw for 5 mgDraw for 10 mg
10 mg powder1 mL10 mg/mL0.5 mL = 50 units U-1001 mL = 100 units (whole vial)
10 mg powder2 mL5 mg/mL1 mL = 100 units2 mL = whole vial (2 injections or larger syringe)
20 mg powder2 mL10 mg/mL0.5 mL = 50 units1 mL = 100 units

Pinealon reconstitution:

Vial sizeBAC waterConcentrationDraw for 1 mgDraw for 2 mg
10 mg powder2 mL5 mg/mL (5000 mcg/mL)0.2 mL = 20 units U-1000.4 mL = 40 units
20 mg powder2 mL10 mg/mL0.1 mL = 10 units0.2 mL = 20 units
20 mg powder4 mL5 mg/mL0.2 mL = 20 units0.4 mL = 40 units

Storage. Reconstituted DSIP is stable refrigerated at 2-8 °C for approximately 4 weeks. Reconstituted Selank (BAC water or saline) is stable refrigerated for 30 days. Reconstituted Epitalon and Pinealon are stable for at least 4 weeks refrigerated but typically consumed within 10-20 days as part of the course. Lyophilized (unreconstituted) vials are stable at room temperature short-term and refrigerated for extended storage per vendor specification.

For automated math with any vial size and concentration, use the Peptide Toolkit Calculator. Select DSIP, Selank, Epitalon, or Pinealon from the dropdown, enter your vial size and BAC water volume, and it will output the exact draw for your target dose in both mL and U-100 units.

Side Effects and Management

DSIP side effects. The published safety profile in the small human trials that exist is favorable. Reported effects: mild headache in a subset of users, occasional dizziness, morning grogginess if dosed too close to intended wake time (a 6-hour minimum window between injection and wake is a reasonable rule of thumb), vivid dreams in some users, mild injection-site reactions. No standardized long-term safety data exist because no long-term human trials have been run. If morning grogginess appears, move the DSIP injection earlier in the pre-bed window (60 min rather than 30 min). If vivid dreams are unpleasant rather than neutral, lower the dose or move to alternating nights.

Selank side effects. Very benign in Russian clinical data. No sedation during daytime doses. No cognitive dulling. No dependence syndrome. No withdrawal symptoms reported on discontinuation. Rare reports in community sources of transient mild headache in the first few nights. Intranasal administration can cause mild nasal irritation, particularly with BAC-water-reconstituted product; switching to saline reconstitution typically resolves this. Drug interaction flag: SSRIs and SNRIs. Both Selank (via serotonergic enhancement and enkephalinase inhibition) and SSRIs/SNRIs push toward elevated serotonergic tone. No case reports of serotonin syndrome exist, but the directional stacking is theoretically additive. Users on prescribed serotonergic antidepressants should coordinate with their prescriber before starting Selank. Benzodiazepine interaction: additive anxiolytic effect (Kozlovskaya group animal data showed Selank enhances diazepam anxiolysis). Not automatically contraindicated but users on prescribed benzos should coordinate with their prescriber.

Epitalon and Pinealon side effects. No serious adverse events reported across the Khavinson corpus or in community reporting. Occasional reports of mild headache in the first days of a course, transient injection-site reactions, and in Pinealon specifically a subset of users report unusually vivid dreams during the course window (mechanistically consistent with the compound’s proposed CNS activity). No known interactions with SSRIs, benzodiazepines, or alcohol at published-data level. Long-term safety data are thin — the Khavinson corpus spans decades but has been largely single-group.

Combination-specific management. There are no published DSIP × Selank × Epitalon combination studies. The safety reasoning is mechanistic inference from single-peptide data. No known receptor competition (each peptide targets a different system). Additive anxiolytic effect with Selank plus prescribed benzos — coordinate with prescriber. Theoretical additive serotonergic effect with Selank plus SSRIs — no case reports but physician oversight is prudent. Alcohol is the biggest stack-undermining factor. Alcohol suppresses SWS and REM, blunts DSIP’s slow-wave enhancement, and Selank’s anxiolytic benefit is redundant if the user is using alcohol as a sleep aid. Frame alcohol reduction as prerequisite to the stack, not something to layer with it. Pregnancy and lactation: contraindicated for all three (standard research-peptide flag). Immune compromise: Selank has demonstrated immunomodulatory effects (interferon-alpha induction, cytokine balance shift). Users on immunosuppressants should coordinate with their prescriber.

Red flags to discontinue. Persistent morning grogginess despite dose reduction or timing adjustment. New or worsening anxiety on Selank (rare but possible in a small subset of users, particularly those with panic-disorder history). Any signs of serotonin syndrome in a user concurrently on SSRIs (agitation, hyperreflexia, tremor, hyperthermia) — discontinue Selank immediately and seek medical evaluation. Any injection-site reaction that progresses beyond mild redness (spreading warmth, purulent discharge, systemic fever) — discontinue and seek evaluation for infection.

For a broader view of peptide interactions and safety, see our Peptide Lab Testing Guide and consider baseline and follow-up labs (see FAQ below).

Cost Considerations

DSIP monthly cost (nightly use at 200 mcg):

SourceProductMonthly costNotes
Compounding pharmacy5 mg vial with prescription$60 – $1401 vial covers ~25 nights at 200 mcg; 2 vials per month typical
Compounding pharmacy10 mg vial with prescription$90 – $180~50 nights at 200 mcg; ~1.7-month supply
Research peptide vendor5 mg or 10 mg “research use only”$30 – $110Not intended for human use; quality highly variable

Selank monthly cost (nightly pre-bed use):

SourceProductMonthly costNotes
Compounding pharmacyCompounded intranasal solution$80 – $150Physician-supervised, pharmaceutical-grade
Russian pharma import0.15% Selank nasal drops$40 – $80Legal grey zone in US; jurisdictional variation
Research peptide vendorLyophilized 5 mg vial + DIY spray$30 – $70DIY reconstitution required

Epitalon course cost (two 10-day courses per year at 10 mg/day):

SourceProductPer courseAmortized monthly
Compounding pharmacy10 mg vials, 10-day course$80 – $180~$13 – $30/mo
Research peptide vendor10 mg or 100 mg bulk vials$25 – $80~$5 – $15/mo

Pinealon course cost (2-3 courses per year at 1-2 mg/day, 10-20 day courses):

SourceProductPer courseAmortized monthly
Compounding pharmacy10-20 mg vials$60 – $130~$15 – $30/mo
Research peptide vendor10-20 mg vials$40 – $100~$10 – $25/mo

Total stack monthly cost. Running DSIP + Selank nightly with amortized Epitalon (or Pinealon) courses through the compounding-pharmacy path: approximately $150 – $320 per month. Through the research-peptide-vendor path: approximately $60 – $200 per month. For comparison, compounded melatonin from telehealth services runs $150+ per month for just the single-ingredient product, so the full peptide stack is not dramatically more expensive than a well-designed single-ingredient telehealth offering. It is meaningfully more expensive than $5-15/month OTC melatonin at the Cruz-Sanabria-optimized 4 mg dose (PMID 38888087), which is the honest evidence-first comparison.

Related purchases. Bacteriostatic water $10-15 per 30 mL vial. Preservative-free saline for intranasal $8-15. Insulin syringes $15-25 per 100-count box. Nasal spray bottle for DIY Selank $5-10. Alcohol swabs and sharps container trivial cost. Budget an additional $25-40 per month for supplies.

Not to buy from research-peptide vendors on our supplies pages. Per our editorial policy, we do not link to research-peptide suppliers as affiliates on any Peptide Toolkit page. Compounding-pharmacy sourcing via prescription is the recommended path for any peptide administered to humans.

Frequently Asked Questions

How long before I feel the stack working?
Selank’s anxiolytic effect is typically felt within 20-40 minutes of the first intranasal dose. DSIP’s sleep-deepening effect typically becomes noticeable over 3-7 nights of consistent nightly use. Epitalon or Pinealon course effects trail 2-4 weeks post-course completion because the mechanism is upstream circadian re-anchoring rather than acute sleep induction. If a user expects an immediate Ambien-like knockout effect, the stack will disappoint. If the user is tracking subjective sleep quality, morning restedness, and time-to-sleep-onset over 2-4 weeks, the effect should be discernible.

Isn’t Semax also a sleep peptide?
No. This is a common misconception. Semax (Met-Glu-His-Phe-Pro-Gly-Pro, a synthetic ACTH(4-10) analog) is activating, not sedative. Its documented effects include BDNF upregulation, mild dopaminergic modulation, and cognitive enhancement (PMIDs 18204410, 20387390). Evening dosing of Semax reliably interferes with sleep for most users. The community consensus is a 2 PM cutoff for Semax to preserve sleep. If a user has confused Semax with Selank because both are Russian-developed intranasal peptides, this is understandable but consequential: swapping them nightly would keep the user awake, not put them to sleep. See our Semax vs Selank comparison for full detail. Semax is not a sleep peptide.

Can I add CJC-1295 + Ipamorelin for growth-hormone-mediated deep sleep?
Some male users do, targeting nocturnal GH pulse restoration and the well-documented GHRH-to-slow-wave-sleep coupling (Steiger corpus, PMIDs 1361964, 15538933, 16912060, 12388174). This is not recommended for women. A 2007 Steiger study (PMID 17850984) showed peripheral GHRH impairs sleep in healthy young women and elevates ACTH and cortisol — the opposite of the intended effect. The GHRH-analog slow-wave enhancement documented in the Steiger corpus is essentially male-specific in the published literature. Male users considering this add-on: 100-200 mcg CJC-1295-no-DAC + 100-200 mcg Ipamorelin SC, 30-60 minutes pre-bed, some protocols 5 nights on / 2 off. See our CJC-1295 Guide, Ipamorelin Guide, and CJC-1295 vs Ipamorelin comparison for full pharmacology and dosing. Also: importantly, GH-analog stacking adds significant monthly cost ($150-400) and moves the intervention into “recovery / body composition” territory, not pure sleep restoration.

Should I try melatonin first before the stack?
Yes. Honestly. Melatonin has a substantially better evidence base than any peptide in this stack. Cruz-Sanabria 2024 (PMID 38888087) is a systematic review and dose-response meta-analysis of 26 RCTs with 1,689 observations that established 4 mg oral melatonin taken 3 hours before intended sleep as optimal for sleep-onset latency reduction and total sleep time increase. Cost is $5-15/month OTC. If the user has not tried well-timed melatonin at the evidence-based dose, that is the first-line intervention. The peptide stack is for users whose complaint is either (a) sleep depth / quality despite adequate quantity or timing (DSIP-relevant), (b) pre-sleep anxiety / rumination unresponsive to melatonin (Selank-relevant), or (c) documented age-related circadian misalignment (Epitalon-relevant). It is not the first thing to try.

Can I run this stack with prescribed SSRIs or SNRIs?
Coordinate with your prescriber. Selank’s serotonergic and enkephalinase-inhibition mechanisms push in the same direction as SSRIs, creating a theoretical additive risk. No case reports of serotonin syndrome exist in the published or community reporting base, but the directional stacking is real. DSIP has no documented serotonergic activity. Epitalon and Pinealon have no documented serotonergic activity. The Conservative variant of the stack (Selank alone first, staged addition of DSIP, deferred Epitalon course) is designed in part to accommodate careful introduction under prescriber oversight.

Can I run this stack with prescribed benzodiazepines?
Coordinate with your prescriber. Selank plus benzodiazepines is additive at the anxiolytic level per Kozlovskaya-group animal data (Selank enhances diazepam anxiolysis). This is not automatically contraindicated, but the additivity means the effective benzodiazepine dose is functionally higher on Selank. Users may find that they can reduce prescribed benzo dose under physician supervision after establishing Selank benefit, but this is a physician-driven decision, not a self-directed one.

What if I drink alcohol at night?
The stack will underperform. Alcohol suppresses slow-wave sleep and REM, exactly the phases DSIP is supposed to enhance. Alcohol also blunts the perceived need for Selank’s anxiolytic effect because alcohol is itself a GABAergic anxiolytic (with much worse tolerance and dependence signaling than Selank). The honest recommendation is to eliminate alcohol within 3 hours of intended sleep before running the stack, and ideally reduce total alcohol intake substantially. Running the stack while drinking nightly is spending peptide dollars to work around a self-inflicted sleep disruption.

How long can I stay on the stack?
DSIP and Selank are nightly-tolerated per community reports but the cycling patterns (Selank 14 on / 7 off; DSIP 3-4 weeks on / 1-2 weeks off) are conservative defaults that preserve subjective effect. Epitalon and Pinealon are cyclical by mechanism — 10-20 day courses two to three times per year. There is no established maximum duration for continuous use of any of these peptides because long-term human safety data do not exist at scale. The community pattern is periodic reassessment: after 3-6 months on the full stack, take a 2-4 week break from all three, notice whether sleep quality drops materially (indicating real stack benefit) or stays similar (indicating either placebo response or that the underlying condition has resolved), then resume or discontinue based on that.

What labs should I consider?
Baseline and periodic labs are not strictly required for this stack — the peptides are not known to affect the standard metabolic or hepatic panels. If the user wants to characterize their sleep and circadian baseline before starting, considerations include: fasting morning cortisol (elevated cortisol is a common driver of sleep-onset difficulty), TSH and free T4 (thyroid dysfunction is a common occult driver of sleep disruption), 25-hydroxyvitamin D (deficiency correlates with sleep disorders), and if age 45+ or symptoms suggest circadian misalignment, salivary or urinary 6-sulfatoxymelatonin (the standard proxy for endogenous melatonin production). See our Peptide Lab Testing Guide. A consumer sleep tracker (Oura, Whoop, Fitbit, or under-mattress trackers like Withings) provides useful subjective and objective tracking of sleep duration, SWS estimate, and morning readiness even if lab-grade polysomnography is not accessible.

When NOT to run this stack?
Pregnancy or breastfeeding (all three peptides). Untreated primary sleep pathology — obstructive sleep apnea, restless legs syndrome, narcolepsy, or REM sleep behavior disorder — should be diagnosed and managed medically before layering research peptides on top. Active psychiatric decompensation (untreated bipolar disorder, active psychosis, severe major depressive episode) requires psychiatric management, not peptides. Concurrent heavy alcohol use (see above). Concurrent illicit stimulant use. Users on prescribed SSRIs/SNRIs, benzodiazepines, or immunosuppressants who cannot coordinate with their prescriber. Users seeking Semax for sleep (Semax is activating, not sedative — see above).

References

All PMIDs below are drawn from the source dossier at RESEARCH-sleep-stack-and-pillar.md. Confirmed-list citations are lifted from PubMed URLs returned directly during the research pass. Items flagged [VERIFY] must be independently reverified before publication per rule #530.

  1. Schoenenberger GA, Monnier M. Characterization of a delta-EEG-active peptide from cerebral hemodialysate. Experientia. 1977. PMID 265572.
  2. Schoenenberger GA, et al. DSIP amino acid analysis and synthesis. PMID 568769.
  3. Schneider-Helmert D, Schoenenberger GA. Effects of DSIP in disturbed human sleep. Experientia. 1981;37(9):913-917. PMID 7028502.
  4. Kastin AJ, et al. Effects of DSIP in man: multifunctional psychophysiological effects. PMID 6689058.
  5. Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. PMID 6145137.
  6. DSIP characterization, properties, and multivariate functions. PMID 6548966.
  7. Pharmacological effects of DSIP. PMID 6548967.
  8. Diurnal rhythm of plasma DSIP in humans. PMID 8175965.
  9. DSIP synthetic nonapeptide comparative properties. PMID 862769.
  10. Kovalzon VM. Delta sleep-inducing peptide (DSIP): a still-unresolved riddle. Journal of Neurochemistry. 2006. [VERIFY exact PMID].
  11. Bes F, et al. DSIP sleep effects in insomniacs, 1992. [VERIFY exact PMID — flagged in dossier as unable to confirm end-to-end].
  12. Zozulya AA, et al. Selank inhibition of enkephalin-degrading enzymes. 2001. PMID 11550013.
  13. Volkova AV, et al. GABAergic gene expression modulation by Selank and Olanzapine in IMR-32 cells. 2017. PMID 28293190.
  14. Kolomin TA, et al. Selank hippocampus BDNF transcriptomics, 2013. [VERIFY exact PMID].
  15. Khavinson VKh, et al. Synthetic tetrapeptide Epitalon restores neuroendocrine regulation in senescent Macaca mulatta. Neuro Endocrinol Lett. 2001;22:251. PMID 11524632.
  16. Korenevsky AV, Anisimov VN, Khavinson VKh. Epithalamin restores epiphyseal melatonin-producing circadian rhythm in elderly people. Bull Exp Biol Med. 2004. PMID 15452611.
  17. Goncharova ND, et al. Normalizing effect of pineal gland peptides on daily melatonin rhythm in old monkeys and elderly people. 2007. PMID 17969590.
  18. Ostroumova TA, et al. Epitalon geroprotective and neuroendocrine effects: 25-year overview. Biomedicines. 2025. PMID 40141333.
  19. Steiger A, et al. GHRH increases slow-wave sleep in male controls. PMID 1361964.
  20. Blockade of endogenous GHRH receptors dissociates GH from slow-wave sleep. PMID 15538933.
  21. GHRH plus CRH enhance NREM after sleep deprivation. PMID 16912060.
  22. Weikel JC, et al. Ghrelin promotes slow-wave sleep in humans. PMID 12388174.
  23. Systemic growth hormone does not affect human sleep. PMID 8501147.
  24. Steiger A, et al. GHRH impairs sleep in healthy young women (sex-dimorphic effect). 2007. PMID 17850984.
  25. Vinkers CH, et al. Benzodiazepine tolerance mechanisms: a review. 2012. PMID 22536226.
  26. Cruz-Sanabria F, et al. Melatonin dose-response meta-analysis. Journal of Pineal Research. 2024. PMID 38888087.
  27. Levitskaya NG, Kaplan AYa. Semax therapeutic possibility for depression. PMID 18204410.
  28. Semax modulation of emotional state compared to cholecystokinin-tetrapeptide in rats. PMID 20387390.
  29. US Department of Health and Human Services. Peptide framework revision. Federal Register. February 27, 2026. [VERIFY document number].

Get peptide updates

Monthly peptide updates and FDA alerts. No spam, unsubscribe anytime.

Last reviewed 2026-07-12 by New Science Labs LLC. This article is educational and does not constitute medical advice.

—

Similar Posts